Effect of Guava Leaf Extract on Aeromonas Hydrophila Bacteria
DOI:
Abstract
Guava leaves (Psidium guajava L.) contain terpenoids, alkaloids, flavonoids, saponins and tannins, which are believed to have antibacterial properties against Aeromonas hydrophila. Aeromonas hydrophila bacteria are bacteria that are pathogenic and cause systemic disease. This research was conducted to determine the effectiveness of guava leaves in inhibiting Aeromonas hydrophil bacteria. The method used in the antibacterial activity test was the diffusion method using the paper disc technique. The results of the One-Way ANOVA test at the 5% level and followed by the Tukey test showed that the effective inhibitory concentration was 7900 ppm with a moderate antibacterial category.
Downloads
Views : 182
Downloads : 164
References
A. A. Justiz Vaillant, A. Goyal, and M. A. Varacallo, “Systemic Lupus Erythematosus,” StatPearls [Internet], Treasure Island, FL: StatPearls Publishing, updated Aug. 4, 2023.
N. T. Ratanasiripong, S. Cahill, C. Crane, and P. Ratanasiripong, “The outcomes of an e-wellness program for lupus patients in Thailand: A participatory action research approach,” Journal of Preventive Medicine and Public Health, vol. 56, no. 2, pp. 154–163, 2023.
S. Molina-Rios, R. Rojas-Martinez, G. M. Estévez-Ramirez, and Y. F. Medina, “Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination: A case report,” Modern Rheumatology Case Reports, vol. 7, no. 1, pp. 43–46, 2023.
A. M. Téllez Arévalo, A. Quaye, L. C. Rojas-Rodríguez, B. D. Poole, D. Baracaldo-Santamaría, and C. M. Tellez Freitas, “Synthetic pharmacotherapy for systemic lupus erythematosus: Potential mechanisms of action, efficacy, and safety,” Medicina (Kaunas), vol. 59, no. 1, 2022.
S. Gavan, I. Bruce, and K. Payne, “Generating evidence to inform health technology assessment of treatments for SLE: A systematic review of decision-analytic model-based economic evaluations,” LUPUS Science & Medicine, vol. 7, no. 1, 2020.
H. Lou, G. S. Ling, and X. Cao, “Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target,” Journal of Autoimmunity, vol. 132, 2022.
K. A. Kirou and R. Fernandez Ruiz, “Neuropsychiatric SLE: Lupus and the Brain,” Rheumatology, [Online]. Created by physicians and experts. Available: https://www.hss.edu/conditions_neuropsychiatric-sle-lupus-and-brain.asp. [Accessed: Jan. 22, 2024].
M. A. Ameer et al., “An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management,” Cureus, vol. 14, no. 10, 2022.
J.-Y. Han, S.-K. Cho, and Y.-K. Sung, “Epidemiology of systemic lupus erythematosus in Korea,” Journal of Rheumatic Diseases, vol. 30, no. 4, pp. 211–219, 2023.
S. R. Vaidya and N. R. Aeddula, “Chronic Kidney Disease,” StatPearls [Internet], Treasure Island, FL: StatPearls Publishing, updated Jul. 31, 2024
G. D. Walters, N. S. Willis, T. E. Cooper, and J. C. Craig, “Interventions for renal vasculitis in adults,” Cochrane Database of Systematic Reviews, vol. 1, no. 1, 2020.
Y. Puckett, A. Gabbar, and A. A. Bokhari, “Prednisone,” StatPearls [Internet], Treasure Island, FL: StatPearls Publishing, updated Jul. 19, 2023
M. Yasir, A. Goyal, and S. Sonthalia, “Corticosteroid adverse effects,” StatPearls [Internet], Treasure Island, FL: StatPearls Publishing, updated Jul. 3, 2023. Available: https: //www.ncbi.nlm.nih.gov/books/NBK531462/.
I. H. Yusuf, P. Charbel Issa, and S. J. Ahn, “Hydroxychloroquine-induced retinal toxicity,” Frontiers in Pharmacology, vol. 14, 2023.
T. H. Baryakova, B. H. Pogostin, R. Langer, and K. J. McHugh, “Overcoming barriers to patient adherence: The case for developing innovative drug delivery systems,” Nature Reviews Drug Discovery, vol. 22, no. 5, pp. 387–409, 2023.
M. F. Sazali et al., “Improving tuberculosis medication adherence: The potential of integrating digital technology and health belief model,” Tuberculosis and Respiratory Diseases (Seoul), vol. 86, no. 2, pp. 82–93, 2023.
T. K. Kvien, K. Patel, and V. Strand, “The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems,” Seminars in Arthritis and Rheumatism, vol. 52, 2022.
